Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) have earned an average rating of “Hold” from the six brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $6.25.
A number of brokerages have weighed in on CPRX. Piper Jaffray Companies set a $8.00 target price on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 1st. BidaskClub lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 7th. SunTrust Banks reiterated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Wednesday, November 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, December 21st.
Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded down $0.05 during trading hours on Friday, reaching $2.75. The company’s stock had a trading volume of 697,379 shares, compared to its average volume of 624,926. Catalyst Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $4.51.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.06). equities analysts forecast that Catalyst Pharmaceuticals will post -0.34 earnings per share for the current year.
Large investors have recently made changes to their positions in the stock. Broadfin Capital LLC raised its holdings in shares of Catalyst Pharmaceuticals by 3.0% during the 4th quarter. Broadfin Capital LLC now owns 7,097,300 shares of the biopharmaceutical company’s stock worth $27,750,000 after acquiring an additional 204,800 shares in the last quarter. Consonance Capital Management LP raised its holdings in shares of Catalyst Pharmaceuticals by 1,111.4% during the 4th quarter. Consonance Capital Management LP now owns 4,473,607 shares of the biopharmaceutical company’s stock worth $17,492,000 after acquiring an additional 4,104,309 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 8.0% during the 4th quarter. BlackRock Inc. now owns 4,019,581 shares of the biopharmaceutical company’s stock worth $15,717,000 after acquiring an additional 298,044 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 11.3% during the 2nd quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock worth $9,242,000 after acquiring an additional 340,614 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $8,082,000. Institutional investors own 54.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thestockobserver.com/2018/03/20/analysts-set-catalyst-pharmaceuticals-inc-cprx-price-target-at-6-25.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.